Brought to you by 
OSE Pharma completes €21.1mm IPO on Euronext
14 Apr 2015
Executive Summary
Three-year-old cancer immunotherapeutics firm OSE Pharma SA completed its oversubscribed initial public offering on Euronext, bringing in €21.1mm ($23.1mm) through the sale of 1.96mm shares at €10.80 (the high end of the company’s intended range of €8-10.80).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
OSE Pharma completes €21.1mm IPO on Euronext
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice